Pasithea Therapeutics Corp.
KTTAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Pasithea Therapeutics Corp. (KTTA) is listed under Biotechnology. The $13.5M market capitalization puts KTTA squarely in micro-cap range for its industry. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Market Cap
$13.5M
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-0.88
EPS (TTM)
$-1.59
EPS (Fwd)
$-0.46
ROE
-65.5%
ROA
-36.0%
Cash
$45.7M
Total Debt
$0
Free CF
-$12.2M
52W Change
-42.8%
Annual Financials
Cash vs Debt
Where KTTA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KTTA finished 30.51% below its 150-day moving average ($0.59) and 37.88% below its 200-day moving average ($0.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KTTA overbought or oversold?
At the October 20, 2026 close, KTTA's RSI(14) was 25.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pasithea Therapeutics Corp. reports $45.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$12.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -65.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Pasithea Therapeutics Corp. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing KTTA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.